Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Al-Ramahi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al-Ramahi, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 14, No. 10, 2421-2422, October 1999
© 1999 European Society of Human Reproduction and Embryology

Debate continued

Severe OHSS: Decreasing the risk of severe ovarian hyperstimulation syndrome

M. Al-Ramahi

Department of Obstetrics and Gynecology, PO Box 35295, Jordan University Hospital, Amman-11180, Jordan

Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of ovulation induction. The frequency of OHSS has increased with the introduction of menotrophins used for controlled ovarian stimulation in assisted reproductive technologies (ART) as an active strategy for the management of different causes of infertility. With the introduction of gonadotrophin-releasing hormone (GnRH) agonists and the use of higher doses of menotrophins to retrieve a higher number of mature oocytes to maximize ART pregnancy rates, the incidence of severe OHSS has been increased. After in-vitro fertilization (IVF) and embryo transfer, the overall . . . [Full Text of this Article]

Acknowledgments

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
P. Aramwit, K. Pruksananonda, N. Kasettratat, and K. Jammeechai
Risk factors for ovarian hyperstimulation syndrome in Thai patients using gonadotropins for in vitro fertilization
Am. J. Health Syst. Pharm., June 15, 2008; 65(12): 1148 - 1153.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J. Bellver, E. A. Munoz, A. Ballesteros, S. R. Soares, E. Bosch, C. Simon, A. Pellicer, and J. Remohi
Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study
Hum. Reprod., November 1, 2003; 18(11): 2283 - 2288.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J. Bellver, E. Escudero, and A. Pellicer
Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome (OHSS): Ovarian mutilating surgery is not an option in the management of severe OHSS
Hum. Reprod., July 1, 2003; 18(7): 1363 - 1367.
[Abstract] [Full Text] [PDF]